<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01710488</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT N. 2008-003842-27</org_study_id>
    <nct_id>NCT01710488</nct_id>
  </id_info>
  <brief_title>Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD</brief_title>
  <acronym>FLOR</acronym>
  <official_title>A Randomized, Controlled, Single-blind, Parallel-group Comparison Between Levofloxacin and Prulifloxacin, in Patients With Acute Exacerbation of COPD Unresponsive to Other Antibiotics and Admitted to the Internal Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fadoi Foundation, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fadoi Foundation, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the percentage of patients with
      &quot;therapeutic success&quot; at the end of the cycle of antibiotic therapy (10 days), in the two
      treatment groups (levofloxacin and prulifloxacin). The effect of study treatments will be
      evaluated on the basis of a score determined in relation to the signs-symptoms of acute
      exacerbation of COPD (sputum purulence, sputum volume, cough, dyspnea, fever)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study was to examine the effects of the use of fluoroquinolones a class of
      antibiotics introduced relatively recently, in a particular population of patients with acute
      exacerbation of COPD, previously treated unsuccessfully with other antibiotics, and
      hospitalized in Internal Medicine. These patients reflect the reality of patients admitted to
      Internal Medicine, they are characterized by a high frequency of advanced age, polypathology,
      with multiple treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of the study is to determine the percentage of patients with &quot;therapeutic success&quot; at the end of the cycle of antibiotic therapy (10 days), in the two treatment groups (levofloxacin and prulifloxacin).</measure>
    <time_frame>10 days</time_frame>
    <description>The effect of study treatments will be evaluated on the basis of a score determined in relation to the signs-symptoms of acute exacerbation of COPD (sputum purulence, sputum volume, cough, dyspnea, fever)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of successful treatment to day 7 of treatment</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>rehospitalization for COPD exacerbation during the follow-up</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of episodes of Exacerbations</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Additional cycles of antibiotic</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>survival</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>COPD Exacerbation</condition>
  <arm_group>
    <arm_group_label>Levofloxacin 1 tablet 500 mg once a day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin 1 tablet 500 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prulifloxacin 1 tablet 600 mg once a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prulifloxacin 1 tablet 600 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 1 tablet 500 mg once a day</intervention_name>
    <description>Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:
Levofloxacin 500 mg (1 tablet) once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food.</description>
    <arm_group_label>Levofloxacin 1 tablet 500 mg once a day</arm_group_label>
    <other_name>LEVOXACIN 500 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prulifloxacin 1 tablet 600 mg once a day</intervention_name>
    <description>Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:
Prulifloxacin 1 tablet 600 mg once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food.</description>
    <arm_group_label>Prulifloxacin 1 tablet 600 mg once a day</arm_group_label>
    <other_name>UNIDROX 600 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Presence of purulent sputum documented by colorimetric assay (Allegra et al., Resp
             Med 2005), plus at least two of the following signs-symptoms

          -  Increased cough

          -  Increased dyspnea

          -  Increase in sputum volume appeared at least 3 days

          -  previous antibiotic treatment with any medication (eg, amoxicillin, amoxicillin /
             clavulanate, cephalosporins or macrolides) with the exception of quinolones, conducted
             for at least 3 days with persistence or worsening of symptoms and subsequent use of
             hospital

          -  ≥ 60 years

          -  FEV1 &lt;80% and ≥ 30% and ratio FEV 1 / FVC &lt;70%

          -  chest x-ray negative for inflammatory infiltrates

          -  informed consent

        Exclusion Criteria:

          -  asthma

          -  pulmonary neoplasms

          -  a history of allergy or hypersensitivity to quinolones

          -  impracticability in oral antibiotic and / or altered ability to absorption by the
             gastrointestinal system

          -  a history of epilepsy, seizures, cerebral vascular disease (stroke cerebri within 6
             months)

          -  history of tendinopathy

          -  note or severe renal impairment creatinine&gt; than twice the upper limit of the normal
             range or hepatic impairment (AST and / or ALT&gt; twice the upper limit of the normal
             range)

          -  patients with sepsis, tuberculosis or other infections in other organs or systems

          -  cystic fibrosis

          -  patients with inherited tolerance to intolerance, Lapp lactase deficiency or
             glucose-galactose malabsorption, or deficiency of the enzyme glucose-6-phosphate
             dehydrogenase

          -  pregnant or breastfeeding

          -  drug or alcohol addiction

          -  experimental concomitant treatment with other drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gualberto GG Gussoni, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. Clinical Research &quot;Study Centre&quot; - FadoiFoundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospita &quot;San Francesco Caracciolo&quot;</name>
      <address>
        <city>Agnone</city>
        <zip>86081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Alghero</name>
      <address>
        <city>Alghero</city>
        <zip>07041</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Cardinal Massaia&quot;</name>
      <address>
        <city>Asti</city>
        <zip>14100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Fatebenefratelli&quot;</name>
      <address>
        <city>Benevento</city>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Bordighera</name>
      <address>
        <city>Bordighera</city>
        <zip>18012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;San Giovanni di Dio&quot;</name>
      <address>
        <city>Cagliari</city>
        <zip>09124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Pugliese-Ciaccio&quot;</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;L.Parodi Delfino&quot;</name>
      <address>
        <city>Colleferro</city>
        <zip>00034</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospita &quot;San Giovanni di Dio&quot;</name>
      <address>
        <city>Crotone</city>
        <zip>88900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;E.Profili&quot; of Fabriano</name>
      <address>
        <city>Fabriano</city>
        <zip>60044</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;F. Veneziale&quot;</name>
      <address>
        <city>Isernia</city>
        <zip>86170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civile Legnano</name>
      <address>
        <city>Legnano</city>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Ortona</name>
      <address>
        <city>Ortona</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fatebenefratelli &quot;Buccheri La Ferla&quot;</name>
      <address>
        <city>Palermo</city>
        <zip>90123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Sant'Anna&quot;</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot; Santa Maria Nuova&quot;</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Policlinico Universitario Campus Biomedico&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Casa Sollievo della Sofferenza&quot;</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Scandiano</name>
      <address>
        <city>Scandiano</city>
        <zip>42019</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Paolo Dettori&quot;</name>
      <address>
        <city>Tempio Pausania</city>
        <zip>0729</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Santa Maria&quot; of Terni</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;San Giovanni Bosco&quot;</name>
      <address>
        <city>Torino</city>
        <zip>10100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Jazzolino&quot;</name>
      <address>
        <city>Vibo Valentia</city>
        <zip>89900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;San Bortolo&quot;</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Santa Maria Maddalena&quot;</name>
      <address>
        <city>Volterra</city>
        <zip>56048</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2012</study_first_submitted>
  <study_first_submitted_qc>October 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2012</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD exacerbation</keyword>
  <keyword>fluoroquinolones,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Prulifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

